



DISCOVERY LABORATORIES, INC.

DISCOVERY LABORATORIES APPOINTS DR. VINCENT BENN VICE PRESIDENT of CLINICAL OPERATIONS

Doylestown, PA — February 11, 2003 — Discovery Laboratories, Inc. (Nasdaq: DSCO), a late-stage specialty pharmaceutical company leveraging its technology in humanized lung surfactants to develop novel respiratory therapies today announced the appointment of Vincent J. Benn, Ph.D., M.B.A., to the position of Vice President, Clinical Operations. Dr. Benn will be responsible for all clinical operations, reporting directly to Christopher J. Schaber, Executive Vice President and Chief Operating Officer.

Dr. Benn brings more than 20 years of experience in all aspects of clinical trials for major pharmaceutical companies with an expertise in pulmonary and respiratory diseases. Most recently, Dr. Benn held the position of Global Clinical Program Director at Aventis Behring, LLC where he was responsible for the clinical development programs in respiratory and critical care medicine. Formerly, he held a number of increasingly senior clinical positions at major pharmaceutical companies including Schering Corporation, Merck and Company, Rhone-Poulenc Rorer, Inc., and Ortho Pharmaceutical Corporation.

Christopher J. Schaber, Executive Vice President and Chief Operating Officer of Discovery Laboratories stated, “We are extremely pleased to have Dr. Benn in this critical role. He brings a wealth of clinical and regulatory experience in developing respiratory therapeutics, especially asthma and chronic obstructive pulmonary disease (COPD). First and foremost, we are very fortunate to have Dr. Benn’s experience applied to our Phase 3 trials in Respiratory Distress Syndrome in premature infants and the upcoming expected New Drug Application (NDA) filing, and the planning and design of a potential Phase 3 clinical trial for Acute Respiratory Distress Syndrome in adults. His skills and leadership are an excellent fit to our team as we develop and commercialize our humanized surfactant technology for respiratory medicine.”

Dr. Benn received his Ph.D. in Immunology from Rutgers University, an M.B.A. in Business Administration from Temple University, and an M.S. in Physiology and Zoology from Rutgers University. Dr. Benn is also Regulatory Affairs certified through the Regulatory Affairs Professional Society.

About Discovery Laboratories

Discovery Laboratories, Inc. is a specialty pharmaceutical company leveraging the only platform technology in humanized lung surfactants to develop a number of potential novel respiratory therapies. Surfactants are produced naturally in the lungs and are critical to all air-breathing mammals. Discovery’s technology is being developed initially for critical care patients with life-threatening respiratory disorders where there are few or no approved therapies available. Surfaxin[®], Discovery’s lead product, is currently in Phase 3 clinical trials for Respiratory Distress Syndrome (RDS) in premature infants, a Phase 3 clinical trial for Meconium Aspiration Syndrome (MAS) in full-term infants, and a Phase 2 clinical trial for Acute Respiratory Distress Syndrome (ARDS) in adults. Aerosol formulations are being developed in an effort to treat other respiratory conditions including

asthma, chronic obstructive pulmonary disease, upper airway diseases and acute lung injury. Discovery is developing a dedicated sales and marketing capability through a collaboration with Quintiles for the United States, and has a strategic alliance with Esteve for Europe and Latin America. Interested parties can receive corporate updates by sending their email addresses to dsco@focuspartners.com. More information about Discovery Laboratories is available on the Company's Web site at www.discoverylabs.com.

To the extent that statements in this press release are not strictly historical, including statements as to the Company's business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's product development, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are the risk that financial conditions may change, the risk that the Company will not be able to raise additional capital or enter into additional collaboration agreements, risks relating to the progress of the Company's research and development and the development of competing therapies and/or technologies by other companies. Those associated risks and others are further described in the Company's periodic filings with the Securities and Exchange Commission including the most recent reports on Forms 10-KSB, 8-K, 10-QSB and 10-Q, and amendments thereto.

###